Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Recent Research on Diabetes Mellitus, Non-Hodgkin Lymphoma Link

October 18, 2019
By Leanne Marcello, MS
News
Article

After conflicting opinions over the years, a study published in the journal Hematology explores the association between diabetes mellitus non-hodgkin lymphoma.

After conflicting opinions over the years, a study published in the journal Hematology found a definitive association between diabetes mellitus (DM) and a greater risk of non-hodgkin lymphoma (NHL).

Diabetes mellitus is a leading public health threat worldwide, and one that affects 3–4% of adults globally. DM contributes to as many as 1.3 million deaths around the globe each year. Scientists predict that DM will be among the five leading disease burdens worldwide by the year 2030. It has previously been established in myriad research that diabetes mellitus is a significant risk factor in the development or prognosis of many disease processes. A diagnosis of DM puts people at risk for cardiovascular disease, dementia, kidney failure, liver ailments, and a number of solid tumors, including those of the pancreas, colon, liver, breast, ovaries, endometrium, lung, and prostate. In addition, prior meta-analyses suggest that DM patients might be at greater risk for one or more hematologic malignancies as well.

Non-Hodgkin lymphoma is a fairly prevalent blood cancer that arises from lymphocytes. It is found more often in developed countries and represents 4.3% of all new cancer diagnoses in the United States. In recent years, it has ranked as high as 7th in males and 6th in females as leading cancer. NHL has been on the rise in Western countries in the new century, particularly in the white, male, and elderly populations. Researchers have labored to identify the pathophysiology of NHL, but they have yet to narrow down its causes.

Although a recent study in Japan, showed that males with DM were at greater risk of developing NHL, while females were not, the relationship between DM and lifetime risk of NHL is something researchers have not yet come to an agreement on either.

In this meta-analysis of cohort studies, the authors investigated the association between the two.

The authors conducted a systematic search of PubMed, the Cochrane Library, and EmBase to identify eligible studies that began no earlier than September of 2018, which led them to 13 cohort studies with a combined total of 9024761 participants. THe researchers discovered that DM was repeatedly associated with an increased risk of NHL (RR = 1.15, 95%CI: 1.02, 1.30, P = .03). Conducting analyses of subgroups, the authors found that DM was most frequently associated with patients under the age of 60 years (RR = 1.65, 95%CI: 1.31, 2.09, P < .0001), follow-up duration within 8 years (RR = 1.23, 95%CI: 1.02, 1.48, P = .03), and studies adjusted for body mass index (RR = 1.35, 95%CI: 1.01, 1.79, P = .04). The investigators also determined that men with DM were more likely to develop NHL than women were (RR = 1.31, 95%CI: 1.04, 1.65, P = .02).
The study authors concluded that patients with DM patients are at substantially greater risk of developing NHL in comparison with nondiabetics, and that male patients with diabetes have the greater likelihood in comparison with females. Further studies should be conducted to rule out miscellaneous factors that may have skewed results.

Recent Videos
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
5 experts in this video
5 experts in this video
Related Content
Advertisement

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

Tim Cortese
May 22nd 2025
Article

Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL

Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL

ONCOLOGY Staff
May 17th 2025
Article

CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

Roman Fabbricatore
May 14th 2025
Article

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.


Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)
May 14th 2025
Article

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Related Content
Advertisement

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

Tim Cortese
May 22nd 2025
Article

Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL

Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL

ONCOLOGY Staff
May 17th 2025
Article

CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

Roman Fabbricatore
May 14th 2025
Article

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.


Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)
May 14th 2025
Article

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.